Variable | Men(n = 143) | Women(n = 37) | ||||
---|---|---|---|---|---|---|
Normal (n = 107) | Sarcopenia (n = 36) | P-value | Normal (n = 28) | Sarcopenia (n = 9) | P-value | |
Age, years | 68.1 ± 7.9 | 70.8 ± 8.9 | 0.087 | 70.4 ± 8.2 | 71.6 ± 13.2 | 0.808 |
BMI, kg/m2 | 24.0 ± 3.1 | 23.3 ± 3.7 | 0.283 | 24.4 ± 3.1 | 22.7 ± 3.5 | 0.231 |
Ever smoker, % | 92 (88.8%) | 31 (86.1%) | 0.336 | 3 (10.7%) | 0 (0.0%) | 0.592 |
Smoking history, pack-years | 32.1 ± 23.9 | 29.7 ± 21.5 | 0.594 | 8.3 ± 7.6 | 0 | n/a |
Diabetes, n | 36 (33.6%) | 11 (30.6%) | 0.839 | 8 (28.6%) | 4 (44.4%) | 0.432 |
Use of Statins or Sulfonylureas or Glinides, n | 42 (39.3%) | 11 (30.6%) | 0.427 | 7 (25%) | 6 (66.7%) | 0.042 |
FVC, L | 2.9 ± 0.7 | 2.62 ± 0.84 | 0.096 | 1.8 ± 0.5 | 1.7 ± 0.6 | 0.888 |
FVC, % predicted | 78.9 ± 16.2 | 72.0 ± 18.9 | 0.040 | 73.8 ± 16.3 | 68.7 ± 18.1 | 0.516 |
FEV1, L | 2.3 ± 0.6 | 2.14 ± 0.63 | 0.241 | 1.5 ± 0.4 | 1.5 ± 0.5 | 0.982 |
FEV1, % predicted | 90.4 ± 18.0 | 86.1 ± 21.2 | 0.249 | 88.9 ± 17.8 | 85.3 ± 18.4 | 0.649 |
FEV1/FVC, % | 79.8 ± 9.3 | 82.6 ± 8.1 | 0.117 | 84.6 ± 7.8 | 87.1 ± 6.6 | 0.409 |
DLCO, % predicted | 73.7 ± 22.8 | 64.9 ± 23.9 | 0.065 | 59.8 ± 20.3 | 66.2 ± 22.6 | 0.551 |
T4 level muscle CSA, cm2 | 111.7 ± 17.4 | 74.7 ± 15.6 | < 0.001 | 78.2 ± 14.8 | 50.3 ± 8.3 | < 0.001 |
aT4 level muscle index, cm2/m2 | 40.6 ± 5.8 | 26.86 ± 5.01 | < 0.001 | 33.0 ± 6.0 | 20.8 ± 2.0 | < 0.001 |
T12 Erector spinae muscle CSA, cm2 | 31.8 ± 8.4 | 21.99 ± 7.46 | < 0.001 | 26.0 ± 5.6 | 15.2 ± 5.8 | < 0.001 |
bT12 muscle index, cm2/m2 | 11.6 ± 3.0 | 7.95 ± 2.85 | < 0.001 | 11.0 ± 2.4 | 6.2 ± 2.2 | < 0.001 |
Follow-up time, months | 38.8 ± 21.0 | 31.6 ± 23.8 | 0.087 | 39.7 ± 21.6 | 46.2 ± 34.5 | 0.603 |
GAP Index score | 3.3 ± 1.3 | 4.0 ± 1.6 | 0.012 | 2.7 ± 1.3 | 3.1 ± 2.1 | 0.610 |
1-year survival, number, (%) | 96 (89.7%) | 28 (77.8%) | 0.068 | 26 (92.9%) | 7 (77.8%) | 0.205 |
2-year survival, number, (%) | 86 (80.4%) | 21 (58.3%) | 0.008 | 25 (89.3%) | 6 (66.7%) | 0.109 |